Clinical Benefit of Delamanid (OPC-67683) in the Treatment of Multidrug-Resistant Tuberculosis Patients in China

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

Dennis Falzon, E. Jaramillo, Holger J. Schünemann et al. · European Respiratory Journal · 2011 · 1.1K citations · Full text

Public Health, Pharmacotherapy, Antimicrobial Pharmacotherapy +15

OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice

Makoto Matsumoto, Hiroyuki Hashizume, Tatsuo Tomishige et al. · PLoS Medicine · 2006 · 740 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Delamanid for Multidrug-Resistant Pulmonary Tuberculosis

Maria Tarcela Gler, Vija Skripconoka, Epifanio Sànchez-Garavito et al. · New England Journal of Medicine · 2012 · 737 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru

Carole D. Mitnick, Jaime Bayona, Eda Palacios et al. · New England Journal of Medicine · 2003 · 496 citations · Full text

Public Health, Community Health, Health Sciences +14

The 2011 update of the World Health Organization guidelines for the programmatic management of drug-resistant tuberculosis

Dennis Falzon, Ernesto Jaramillo, Holger J. Schünemann · European Respiratory Journal · 2011 · 394 citations

Public Health, Pharmacology, Antimicrobial Pharmacotherapy +16